Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Recruiting Phase 3 Interventional Study
High Risk Cardiovascular Disease Hypertension High Cardiovascular Risk
Ready to participate?

Review the details below, then apply to join this clinical trial.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Is 18 years or older for patients with established cardiovascular disease (CVD) * Is 55 years or older for patients with high risk for CVD * Has established CVD (defined as coronary, cerebrovascular, or peripheral artery disease) or high risk for CVD * Has treated hypertension…
Contacts

Clinical Trial Information Line

1-877-ALNYLAM

clinicaltrials@alnylam.com

CONTACT

Clinical Trial Information Line

1-877-256-9526

clinicaltrials@alnylam.com

CONTACT